Blueprint for a Million-Dollar Nest Egg in 4 Years

Stock Power Daily: July 15, 2022.

Monkeypox?! Pharma Power Stock Fights This Infectious Virus In addition to COVID-19, we now face the threat of monkeypox in the U.S. According to the Centers for Disease Control and Prevention, 41 states have reported at least one case of monkeypox. Today’s Power Stock has laid the groundwork to treat monkeypox and rates a 93 on our proprietary system. Just when we’d had enough infectious disease madness, another virus is spreading across the U.S. Monkeypox was mainly found in African nations. In May, however, countries including the U.S. began reporting outbreaks. This latest outbreak shines a light on the global antiviral drug market. The value of the antiviral drug market will rise 11.5% by 2026. Today’s Power Stock is a $1 billion player in antiviral drug development — and it’s expanding its lead product to treat monkeypox. Click here or on the image below to find out more! From our Partners at Banyan Hill Publishing. "MaaS": The No. 1 EV Investment Story Nobody Else Is Telling Right Now While electric vehicles are making the headlines, no one is talking about an even bigger mobility story: “MaaS.” This niche is expected to be bigger than artificial intelligence, 5G and cybersecurity … COMBINED. And investors are being handed a once-in-a-lifetime opportunity to get in at the early stage of an emerging technology. Click here now for more details. Check Out Our Most Recent Power Stocks: “STRONG BULLISH” PLAYER IN +$300 BILLION COMMERCIAL INSURANCE INDUSTRY BUY EXCELLENT FINTECH STOCK AS DIGITAL $ TRANSFER INDUSTRY SKYROCKETS DEMAND FOR RAPID TESTS CONTINUES TO EXPLODE: TOP MEDICAL DIAGNOSTIC POWER STOCK Privacy Policy The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482. To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: https://moneyandmarkets.com/contact-us/ Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets permits editors of a publication to recommend a security to subscribers that they own themselves. However, in no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. Any exit after a buy recommendation is made and prior to issuing a sell notification is forbidden. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. (c) 2022 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471) Remove your email from this list: Click here to Unsubscribe